|
1
|
Robert C, Long GV, Brady B, Dutriaux C,
Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,
Kalinka-Warzocha E, et al: Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al KEYNOTE-001 investigators, : Pembrolizumab for the treatment
of non-small-cell lung cancer. N Engl J Med. 372:2018–2028. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Patel SP and Kurzrock R: Pd-l1 expression
as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther.
14:847–856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al KEYNOTE-024 Investigators, : Pembrolizumab versus
chemotherapy for pd-l1-positive non-small-cell lung cancer. N Engl
J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: Pd-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Snyder A, Makarov V, Merghoub T, Yuan J,
Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et
al: Genetic basis for clinical response to CTLA-4 blockade in
melanoma. N Engl J Med. 371:2189–2199. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carbone DP, Reck M, Paz-Ares L, Creelan B,
Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F,
et al CheckMate 026 investigators, : First-line nivolumab in stage
iv or recurrent non-small-cell lung cancer. N Engl J Med.
376:2415–2426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Van Allen EM, Miao D, Schilling B, Shukla
SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger
SM, et al: Genomic correlates of response to CTLA-4 blockade in
metastatic melanoma. Science. 350:207–211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science. 348:124–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rizvi H, Sanchez-Vega F, La K, Chatila W,
Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N,
et al: Molecular determinants of response to anti-programmed cell
death (pd)-1 and anti-programmed death-ligand 1 (pd-l1) blockade in
patients with non-small-cell lung cancer profiled with targeted
next-generation sequencing. J Clin Oncol. 36:633–641. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Samstein RM, Lee CH, Shoushtari AN,
Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ,
Omuro A, et al: Tumor mutational load predicts survival after
immunotherapy across multiple cancer types. Nat Genet. 51:202–206.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yarchoan M, Hopkins A and Jaffee EM: Tumor
mutational burden and response rate to pd-1 inhibition. N Engl J
Med. 377:2500–2501. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rosenberg JE, Hoffman-Censits J, Powles T,
van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH,
Balmanoukian A, Loriot Y, et al: Atezolizumab in patients with
locally advanced and metastatic urothelial carcinoma who have
progressed following treatment with platinum-based chemotherapy: A
single-arm, multicentre, phase 2 trial. Lancet. 387:1909–1920.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brown SD, Warren RL, Gibb EA, Martin SD,
Spinelli JJ, Nelson BH and Holt RA: Neo-antigens predicted by tumor
genome meta-analysis correlate with increased patient survival.
Genome Res. 24:743–750. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schumacher TN and Schreiber RD:
Neoantigens in cancer immunotherapy. Science. 348:69–74. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Anagnostou V, Smith KN, Forde PM, Niknafs
N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N,
et al: Evolution of neoantigen landscape during immune checkpoint
blockade in non-small cell lung cancer. Cancer Discov. 7:264–276.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Büttner R, Longshore JW, López-Ríos F,
Merkelbach-Bruse S, Normanno N, Rouleau E and Penault-Llorca F:
Implementing TMB measurement in clinical practice: Considerations
on assay requirements. ESMO Open. 4:e0004422019. View Article : Google Scholar
|
|
20
|
Alexandrov LB, Nik-Zainal S, Wedge DC,
Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A,
Børresen-Dale AL, et al Australian Pancreatic Cancer Genome
Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq
Consortium; ICGC PedBrain, : Signatures of mutational processes in
human cancer. Nature. 500:415–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lawrence MS, Stojanov P, Polak P, Kryukov
GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH,
Roberts SA, et al: Mutational heterogeneity in cancer and the
search for new cancer-associated genes. Nature. 499:214–218. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ready N, Hellmann MD, Awad MM, Otterson
GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M,
et al: First-line nivolumab plus ipilimumab in advanced
non-small-cell lung cancer (checkmate 568): Outcomes by programmed
death ligand 1 and tumor mutational burden as biomarkers. J Clin
Oncol. 37:992–1000. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cristescu R, Mogg R, Ayers M, Albright A,
Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, et al:
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based
immunotherapy. Science. 362:3622018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Innocenti F, Ou FS, Qu X, Zemla TJ,
Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM,
Blanke CD, et al: Mutational analysis of patients with colorectal
cancer in calgb/swog 80405 identifies new roles of microsatellite
instability and tumor mutational burden for patient outcome. J Clin
Oncol. 37:1217–1227. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Owada-Ozaki Y, Muto S, Takagi H, Inoue T,
Watanabe Y, Fukuhara M, Yamaura T, Okabe N, Matsumura Y, Hasegawa
T, et al: Prognostic impact of tumor mutation burden in patients
with completely resected non-small cell lung cancer: Brief report.
J Thorac Oncol. 13:1217–1221. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chalmers ZR, Connelly CF, Fabrizio D, Gay
L, Ali SM, Ennis R, Schrock A, Campbell B, Shlien A, Chmielecki J,
et al: Analysis of 100,000 human cancer genomes reveals the
landscape of tumor mutational burden. Genome Med. 9:342017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Frampton GM, Fichtenholtz A, Otto GA, Wang
K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, et
al: Development and validation of a clinical cancer genomic
profiling test based on massively parallel DNA sequencing. Nat
Biotechnol. 31:1023–1031. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Roszik J, Haydu LE, Hess KR, Oba J, Joon
AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V,
Tetzlaff MT, et al: Novel algorithmic approach predicts tumor
mutation load and correlates with immunotherapy clinical outcomes
using a defined gene mutation set. BMC Med. 14:1682016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Campesato LF, Barroso-Sousa R, Jimenez L,
Correa BR, Sabbaga J, Hoff PM, Reis LF, Galante PA and Camargo AA:
Comprehensive cancer-gene panels can be used to estimate mutational
load and predict clinical benefit to PD-1 blockade in clinical
practice. Oncotarget. 6:34221–34227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Berg KCG, Eide PW, Eilertsen IA,
Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA,
Eknaes M, Lind GE, et al: Multi-omics of 34 colorectal cancer cell
lines - a resource for biomedical studies. Mol Cancer. 16:1162017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Catalogue Of Somatic Mutations In Cancer
(COSMI), . Cell Lines Project v92, released 27-AUG-20. Available
from. https://cancer.sanger.ac.uk/cell_linesAugust
28–2019
|
|
33
|
Gupta A, Connelly C, Frampton G,
Chmielecki J, Ali S, Suh J, Schrock A, Ross J, Stephens P and
Miller V: The druggable mutation landscape of lung adenocarcinoma.
J Thorac Oncol. 12:9772017. View Article : Google Scholar
|
|
34
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The Cancer Cell Line Encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fenizia F, Pasquale R, Roma C, Bergantino
F, Iannaccone A and Normanno N: Measuring tumor mutation burden in
non-small cell lung cancer: Tissue versus liquid biopsy. Transl
Lung Cancer Res. 7:668–677. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chaudhary R, Quagliata L, Martin JP,
Alborelli I, Cyanam D, Mittal V, Tom W, Au-Young J, Sadis S and
Hyland F: A scalable solution for tumor mutational burden from
formalin-fixed, paraffin-embedded samples using the Oncomine Tumor
Mutation Load Assay. Transl Lung Cancer Res. 7:616–630. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Endris V, Buchhalter I, Allgäuer M, Rempel
E, Lier A, Volckmar AL, Kirchner M, von Winterfeld M, Leichsenring
J, Neumann O, et al: Measurement of tumor mutational burden (TMB)
in routine molecular diagnostics: In silico and real-life analysis
of three larger gene panels. Int J Cancer. 144:2303–2312.
2019.PubMed/NCBI
|
|
38
|
Turajlic S, Litchfield K, Xu H, Rosenthal
R, McGranahan N, Reading JL, Wong YNS, Rowan A, Kanu N, Al Bakir M,
et al: Insertion-and-deletion-derived tumour-specific neoantigens
and the immunogenic phenotype: A pan-cancer analysis. Lancet Oncol.
18:1009–1021. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mandal R, Samstein RM, Lee KW, Havel JJ,
Wang H, Krishna C, Sabio EY, Makarov V, Kuo F, Blecua P, et al:
Genetic diversity of tumors with mismatch repair deficiency
influences anti-PD-1 immunotherapy response. Science. 364:485–491.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chae YK, Viveiros P, Lopes G, Sukhadia B,
Sheikh MM, Saravia D, Florou V, Sokol ES, Frampton GM, Chalmers ZR,
et al: Clinical and immunological implications of frameshift
mutations in lung cancer. J Thorac Oncol. 14:1807–1817. 2019.
View Article : Google Scholar : PubMed/NCBI
|
